Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.
In this episode Nadine chats to CEO + Managing Director at Optiscan (ASX:OIL) Dr Camile Farah, who is also a trained clinician and pathologist.
Together they discuss Optiscan’s recently signed deal with renowned US Health based organisation, the Mayo Clinic. Optiscan is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopy-imaging technologies for medical, translational and pre-clinical applications.
Its technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.The technology development is designed for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.
It could also help alleviate concerns about a growing shortage of pathologists in Australia and internationally delaying medical test results.
To hear Nadine and Camile discuss all this and more, tune in below!
Like to tune in through another app? Just search for Vital Signs with Nadine McGrath and subscribe!
The post Vital Signs Podcast: Optiscan appeared first on Stockhead.
